                         SEQUENCE LISTING

<110>  National Research Council of Canada
 
<120>  Method of Optimizing Peptide Immuno-Epitope by Glycosylation, 
       Optimized Peptide thereof and its Use for Conjugate Vaccines

<130>  5659-59

<150>  US 62/445,778
<151>  2017-01-13

<160>  17    

<170>  PatentIn version 3.5

<210>  1
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HA peptide antigen from the Influenza virus

<400>  1

Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Gly Gly Trp 
1               5                   10                  


<210>  2
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NA peptide antigen from the Influenza virus

<400>  2

Ile Leu Arg Thr Gln Glu Ser Glu Cys 
1               5                   


<210>  3
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Conjugated peptide from the Influenza virus


<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Wherein X represents a modified cysteine conjugated with KLH via 
       a linker

<400>  3

Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Gly Gly Trp Lys Lys 
1               5                   10                  15      


Xaa 
    


<210>  4
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Conjugated peptide from the Influenza virus


<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Wherein X represents a modified cysteine conjugated with TT (or 
       KLH) via a linker

<400>  4

Ile Leu Arg Thr Gln Glu Ser Glu Cys Lys Lys Xaa 
1               5                   10          


<210>  5
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Conjugated peptide from the Influenza virus


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Wherein X represents a modified serine coupled with a sugar

<220>
<221>  MISC_FEATURE
<222>  (18)..(18)
<223>  Wherein X represents a modified cysteine conjugated with TT or 
       KLH via a linker

<400>  5

Xaa Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Gly Gly Trp Lys 
1               5                   10                  15      


Lys Xaa 
        


<210>  6
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Conjugated peptide from the Influenza virus


<220>
<221>  MISC_FEATURE
<222>  (15)..(15)
<223>  Wherein X represents a modified serine coupled with a sugar

<220>
<221>  MISC_FEATURE
<222>  (18)..(18)
<223>  Wherein X represents a modified cysteine conjugated with TT or 
       KLH via a linker

<400>  6

Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Gly Gly Trp Xaa Lys 
1               5                   10                  15      


Lys Xaa 
        


<210>  7
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Conjugated peptide from the Influenza virus


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Wherein X represents a modified serine coupled with a sugar

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Wherein X represents a modified lysine conjugated with KLH via a 
       linker

<400>  7

Xaa Ile Leu Arg Thr Gln Glu Ser Glu Cys Xaa 
1               5                   10      


<210>  8
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Conjugated peptide from the Influenza virus


<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Wherein X represents a modified lysine conjugated with KLH via a 
       linker

<400>  8

Ile Leu Arg Thr Gln Glu Ser Glu Cys Xaa 
1               5                   10  


<210>  9
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Conjugated peptide from the Influenza virus


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Wherein X represents a modified serine coupled with a sugar

<220>
<221>  MISC_FEATURE
<222>  (18)..(18)
<223>  Wherein X represents a biotinylated cysteine

<400>  9

Xaa Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Gly Gly Trp Lys 
1               5                   10                  15      


Lys Xaa 
        


<210>  10
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Conjugated peptide from the Influenza virus


<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Wherein X represents a biotinylated lysine

<400>  10

Arg Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Gly Gly Trp 
1               5                   10                  15      


Xaa 
    


<210>  11
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Conjugated peptide from the Influenza virus


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Wherein X represents a modified serine coupled with a sugar

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Wherein X represents a biotinylated lysine

<400>  11

Xaa Ile Leu Arg Thr Gln Glu Ser Glu Cys Xaa 
1               5                   10      


<210>  12
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Conjugated peptide from the Influenza virus


<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Wherein X represents a biotinylated lysine

<400>  12

Ile Leu Arg Thr Gln Glu Ser Glu Cys Xaa 
1               5                   10  


<210>  13
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Conjugated peptide from the Human epidermal growth factor 
       receptor 2 (HER2)


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Wherein X represents a modified serine coupled with a lactose

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  Wherein X represents a modified cysteine conjugated with KLH via 
       a linker

<400>  13

Xaa Ala Leu Val Thr Tyr Asn Thr Asp Thr Phe Glu Ser Xaa 
1               5                   10                  


<210>  14
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Conjugated peptide from the Human epidermal growth factor 
       receptor 2 (HER2)


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Wherein X represents a modified serine coupled with a lactose

<220>
<221>  MISC_FEATURE
<222>  (15)..(15)
<223>  Wherein X represents a modified cysteine conjugated with KLH via 
       a linker

<400>  14

Xaa Met Pro Asn Pro Glu Gly Arg Tyr Thr Phe Gly Ala Ser Xaa 
1               5                   10                  15  


<210>  15
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide from the Human epidermal growth factor receptor 2 (HER2)

<400>  15

Ala Leu Val Thr Tyr Asn Thr Asp Thr Phe Glu Ser 
1               5                   10          


<210>  16
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide from the Human epidermal growth factor receptor 2 (HER2)

<400>  16

Met Pro Asn Pro Glu Gly Arg Tyr Thr Phe Gly Ala Ser 
1               5                   10              


<210>  17
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide from the Human epidermal growth factor receptor 2 (HER2) 
       - amino acids 270-294

<400>  17

Ala Leu Val Thr Tyr Asn Thr Asp Thr Phe Glu Ser Met Pro Asn Pro 
1               5                   10                  15      


Glu Gly Arg Tyr Thr Phe Gly Ala Ser 
            20                  25  


